In summary, the data presented here for the first time show that TNFRSF1B c.587T>G and c.*922C>T SNV can impact the clinicopathological features of CM and can act as independent prognostic factors in CM patients, and can be used in the future to select CM patients homogeneously treated for differentiated approaches. This evidence concerns the gene TNFRSF1B and cutaneous mastocytosis.